No Data
Spartan Capital Securities, LLC Caps Off a Remarkable Year With Key December Transactions
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement
Lipella Pharmaceuticals Announces Publication In CUREUS On Non-Steroid Treatment Of Oral Lichen Planus Titled "Rationale For The Use Of Topical Calcineurin Inhibitors In The Management Of Oral Lichen Planus And Mucosal Inflammatory Diseases"
Express News | Lipella Pharmaceuticals Announces Publication in Cureus on Non-Steroid Treatment of Oral Lichen Planus
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
Lipella Pharmaceuticals Has Completed Dosing For The First Cohort In Its Phase 2A Trial Of LP-310, A Liposomal-tacrolimus Oral Rinse Being Developed For Oral Lichen Planus, Topline Data Is Expected By Year-end And Complete The Trial By Mid-2025
No Data